SNTI

Senti Biosciences Inc

Add to Watchlist

Advanced Chart

1.950

+0.14(7.735%)1D

Line

Candle

YTD

High

1.950

Open

1.820

VWAP

1.84

Vol

66.16K

Mkt Cap

51.01M

Low

1.8002

Amount

121.78K

EV/EBITDA(TTM)

Total Shares

45.76M

29.44M

EV/OCF(TTM)

P/S(TTM)

Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q3

0.00

-100%

0.000

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Senti Biosciences, Inc. (SNTI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 28.29%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+28.29%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast SNTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNTI is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.950

Low

12.00

Averages

12.00

High

12.00

Current: 1.950

Low

12.00

Averages

12.00

High

12.00

H.C. Wainwright

initiated

$12

2025-10-14

Reason

H.C. Wainwright

Price Target

$12

2025-10-14

initiated

Reason

H.C. Wainwright initiated coverage of Senti Bio with a Buy rating and $12 price target. The firm believes the company's allogeneic CAR-NK cell therapy platform has the potential to treat several cancer types including hematologic malignancies and solid tumors. It views Senti as an "underappreciated CAR-NK player with a differentiated platform with a near-term catalyst" in Q4.

Laidlaw

NULL -> Buy

initiated

2025-06-06

Reason

Laidlaw

Price Target

2025-06-06

initiated

NULL -> Buy

Reason

Chardan Capital

Geulah Livshits

Strong Buy

Maintains

$10 → $12

2024-12-04

Reason

Chardan Capital

Geulah Livshits

Price Target

$10 → $12

2024-12-04

Maintains

Strong Buy

Reason

Chardan Capital

Geulah Livshits

Strong Buy

Maintains

$10

2024-12-02

Reason

Chardan Capital

Geulah Livshits

Price Target

$10

2024-12-02

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Senti Biosciences Inc (SNTI.O) is -1.00, compared to its 5-year average forward P/E of -1.11. For a more detailed relative valuation and DCF analysis to assess Senti Biosciences Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.11

Current PE

-1.00

Overvalued PE

0.32

Undervalued PE

-2.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.76

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.98

Undervalued EV/EBITDA

-2.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

15.68

Current PS

1.95

Overvalued PS

35.26

Undervalued PS

-3.90